Skip to main navigation Skip to search Skip to main content

Emerging therapies for multiple sclerosis

  • Cleveland Clinic Foundation

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

BACKGROUND- Until recently, therapy for multiple sclerosis was limited to management of symptoms and treatment of acute relapses. Increasingly, effective therapies that alter the disease course are becoming available. REVIEW SUMMARY- The purpose of this article is to review emerging drug therapies for multiple sclerosis and to discuss issues that remain controversial. Tizanidine and 4-aminopyridine are two new options for symptomatic management. The role of corticosteroids in the treatment of acute relapses and as chronic therapy is discussed. A comparison is presented of interferon β-1b (Betaseron), interferon β-1a (Avonex), and copolymer-1 (Copaxone), the three options with proven efficacy for relapsing-remitting disease. Finally, a number of other treatment options are in late stages of testing. CONCLUSION- Rapidly, an increasing number of treatment options for multiple sclerosis are emerging.

Original languageEnglish
Pages (from-to)342-355
Number of pages14
JournalNeurologist
Volume2
Issue number6
StatePublished - Nov 1996

Keywords

  • Copolymer-1
  • Corticosteroids
  • Immunosuppression
  • Interferon β-1
  • Oral tolerance
  • Potassium channel blockers
  • Spasticity
  • Symptomatic treatment

Fingerprint

Dive into the research topics of 'Emerging therapies for multiple sclerosis'. Together they form a unique fingerprint.

Cite this